Mega Genomics Ltd
06667
Company Profile
Business description
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Contact
North Garden Road
401 Health Work
Haidian District
Beijing
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
206
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,290.70 | 104.60 | 1.14% |
| CAC 40 | 8,613.82 | 104.18 | 1.22% |
| DAX 40 | 26,001.31 | 372.07 | 1.45% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,857.70 | 10.35 | -0.10% |
| HKSE | 25,900.44 | 108.96 | -0.42% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,337.44 | 417.46 | -0.65% |
| NZX 50 Index | 13,826.09 | 51.16 | 0.37% |
| S&P 500 | 7,600.50 | 110.78 | 1.48% |
| S&P/ASX 200 | 9,126.10 | 103.10 | 1.14% |
| SSE Composite Index | 3,815.59 | 5.93 | 0.16% |